Diversity and divergence of the glioma-infiltrating T-cell receptor repertoireJennifer S. Sims, Jeffrey N. Bruce, Justin A. Neira et al.|Proceedings of the National Academy of Sciences|2016Cited by 107
Abstract CT064: Updated safety and efficacy results from a phase 1/2 study of nezastomig, a first-in-class co-stimulatory PSMA×CD28 bispecific antibody (bsAb), plus cemiplimab (anti-PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)Bilal A. Siddiqui, Elizabeth Miller, Jingsong Zhang et al.|Cancer Research|2025Cited by 3